Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs LENALIDOMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Multiple myeloma (in combination with dexamethasone),Myelodysplastic syndromes associated with deletion 5q,Mantle cell lymphoma (relapsed or refractory)
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Metabolized via hydrolysis and glucuronidation; CYP450 enzymes play a minor role.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
~30% bound, primarily to albumin.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Approximately 0.6 L/kg (range 0.4-0.8 L/kg), indicating distribution into total body water.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Oral: ~80% (range 60-100%); food does not significantly affect absorption.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
For Cr Cl 30-60 m L/min: 5 mg once daily; for Cr Cl <30 m L/min not requiring dialysis: 2.5 mg once daily; for Cr Cl <30 m L/min requiring dialysis: 2.5 mg once daily post-dialysis on dialysis days.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
No specific dose adjustment for hepatic impairment in FDA labeling; use with caution in severe hepatic impairment (Child-Pugh C) due to lack of data.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Not approved in pediatric patients; safety and efficacy not established in patients <18 years.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No specific dose adjustment beyond renal function; monitor for hematologic toxicity and thromboembolic events due to age-related comorbidities and renal impairment.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Embryo-fetal toxicity: Can cause fetal harm. Do not use during pregnancy. Females of reproductive potential must use contraception or abstain. Hematologic toxicity: Significant neutropenia and thrombocytopenia; monitor blood counts. Deep vein thrombosis and pulmonary embolism: Increased risk; monitor and consider prophylaxis.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hematologic toxicity (neutropenia and thrombocytopenia); thromboembolic events; hepatotoxicity; allergic reactions; tumor lysis syndrome; thyroid disorders; neuropathy; increased risk of second primary malignancies.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Pregnancy; hypersensitivity to lenalidomide; concomitant use with live vaccines; breastfeeding not recommended.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) as they inhibit CYP3A4 and may increase lenalidomide exposure. No other significant food interactions. Take capsules with water; do not crush or chew.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects, cardiac anomalies) and fetal death. No adequate studies in second or third trimester, but risk persists throughout pregnancy. Contraindicated in pregnancy.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No data on lenalidomide in human milk; however, due to potential for serious adverse effects in nursing infants (including neutropenia and thrombocytopenia), breastfeeding is contraindicated during therapy and for at least 1 week after last dose. M/P ratio unknown.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Lenalidomide is contraindicated in pregnancy; no dose adjustments are recommended because use is prohibited. No pharmacokinetic studies in pregnancy; however, physiological changes (e.g., increased volume of distribution, renal clearance) may alter drug levels, but given teratogenicity, dosing is not applicable.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Lenalidomide is an immunomodulatory drug (IMi D) with anti-angiogenic and anti-proliferative properties. It requires risk evaluation and mitigation strategy (REMS) due to teratogenicity. Monitor for thromboembolic events (DVT/PE) especially when combined with dexamethasone. Consider dose adjustment for renal impairment (Cr Cl < 60 m L/min). Baseline and periodic monitoring of CBC, thyroid function, and liver enzymes is essential. May cause tumor lysis syndrome in high tumor burden patients; ensure hydration and prophylaxis.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Do not take lenalidomide if you are pregnant, breastfeeding, or planning to become pregnant; use two reliable forms of contraception during treatment and for 4 weeks after stopping.,Do not donate blood or sperm while taking lenalidomide and for 4 weeks after discontinuation.,Report any symptoms of blood clots (swelling, pain, redness in leg, sudden chest pain, shortness of breath) or signs of infection (fever, chills) immediately.,Take lenalidomide exactly as prescribed, usually once daily with a glass of water; do not break, chew, or open capsules.,Avoid grapefruit, grapefruit juice, and Seville oranges as they may affect drug metabolism.,Keep all appointments for blood tests to monitor for low blood cell counts and other side effects.
No interactions on record
"The combination of lenalidomide and leflunomide may result in additive hematologic toxicity, particularly bone marrow suppression, due to overlapping mechanisms that impair hematopoietic cell proliferation and survival. Leflunomide, via its active metabolite teriflunomide, inhibits dihydroorotate dehydrogenase (DHODH) and suppresses pyrimidine synthesis in rapidly dividing cells, while lenalidomide modulates the ubiquitin E3 ligase cereblon, leading to altered cytokine production and direct antineoplastic effects. Clinically, patients may experience increased risks of severe neutropenia, thrombocytopenia, and anemia, potentially requiring dose reductions, growth factor support, or discontinuation of one agent."
"Digoxin, a cardiac glycoside, is a P-glycoprotein (P-gp) substrate. Lenalidomide, an immunomodulatory drug, can inhibit P-gp activity, leading to increased intestinal absorption and reduced renal clearance of digoxin. This interaction may cause elevated serum digoxin levels, increasing the risk of digoxin toxicity (e.g., arrhythmias, nausea, visual disturbances)."
"Lenalidomide, an immunomodulatory drug, increases the thrombogenic potential of Mestranol, an estrogen component of oral contraceptives, by enhancing platelet aggregation and endothelial activation. This combined prothrombotic effect elevates the risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Patients, especially those with additional risk factors, require careful monitoring for signs of thrombosis."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs LENALIDOMIDE, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. LENALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and LENALIDOMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of LENALIDOMIDE is: 10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and LENALIDOMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. LENALIDOMIDE is classified as Category C. Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.